高级搜索
艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌临床疗效观察[J]. 肿瘤防治研究, 2005, 32(05): 313-314. DOI: 10.3971/j.issn.1000-8578.312
引用本文: 艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌临床疗效观察[J]. 肿瘤防治研究, 2005, 32(05): 313-314. DOI: 10.3971/j.issn.1000-8578.312
Clinical Study of Aidi Injection Combined with Transcather Hepatic Arterial Chemoembolization in the Treatment of Primary Liver Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(05): 313-314. DOI: 10.3971/j.issn.1000-8578.312
Citation: Clinical Study of Aidi Injection Combined with Transcather Hepatic Arterial Chemoembolization in the Treatment of Primary Liver Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(05): 313-314. DOI: 10.3971/j.issn.1000-8578.312

艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌临床疗效观察

Clinical Study of Aidi Injection Combined with Transcather Hepatic Arterial Chemoembolization in the Treatment of Primary Liver Cancer

  • 摘要: 目的 观察艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌的疗效。方法 63例原发性肝癌患者随机分为二组,治疗组(33例)为艾迪注射液配合肝动脉化疗及栓塞疗法,对照组(30例)为单纯肝动脉化疗及栓塞。结果 治疗组与对照组的近期客观疗效分别为60.6%和53.3%,临床症状改善率分别为72.7%和33.3%,生存质量改善率分别为54.5%和30.0%。经统计学处理,两组在临床症状及生存质量改善方面差异有显著意义,P<0.05。结论 艾迪注射液配合肝动脉化疗及栓塞治疗原发性肝癌,有助于临床症状的改善和生存质量的提高。

     

    Abstract: Abstract :Objective  To investigate the therapeutic effect of Aidi injection combined with t ranscather hepatic arterial chemoembolization in t reatment for primary liver cancer. Methods  Sixty-three cases with primary liver cancer were randomly divided into two groups. The treated group ( n = 33) received Aidi injection combined with t ranscather hepatic arterial chemoembolization, and the control group ( n = 30 ) were treated with transcather hepatic arterial chemoembolization alone. Results  The response rates in the treated group and control group were 60. 6 % and 53. 3 % respectively . The remission of symptoms were 72. 7 % and 33. 3 % respectively . The improvement of life quantity were 54. 5 % and 30. 3 % respectively. In the clinical symptoms and the quality of life, there were significant difference between the two groups, P < 0. 05. Conclusion  The treatment of Aidi injection combined with t ranscather hepatic arterial chemoembolization was helpful to improve the clinical symptoms and the quality of life for patients with primary liver cancer.

     

/

返回文章
返回